SubsidieMeestersClinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain
Sea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment.
Projectdetails
Introduction
Sea4Us is a world-class biotechnology company with a focus on translating marine-derived compounds with therapeutic potential for unmet medical needs into pharmaceutical assets. Sea4Us has developed a platform focused on drug discovery and development of novel pharmaceuticals based on its core expertise in ion channels and marine biology. Sea4Us is particularly focused on developing and commercializing therapies for chronic pain.
Chronic Pain and Its Impact
Sea4Us has developed a ground-breaking therapeutic drug to treat chronic pain in patients. Chronic pain affects 100 million people across Europe and 1.6 billion globally, and has a devastating impact on quality of life.
Prevalence and Burden
- Pain is the most common reason people visit their doctors.
- It is a leading cause of disability.
- It is a source of enormous social and economic burden, costing Europe alone over 500 billion Euros a year.
Current Treatment Limitations
There are many medications on the market for treating chronic pain, but they are either ineffective for most types of chronic pain and/or have adverse side effects. Opioid drugs are the most effective treatment but also inflict drug addiction, habituation, and other noxious side effects.
Sea4Pain: A Novel Solution
Our novel analgesic molecule, Sea4Pain, has a unique mechanism of action, meaning it is highly effective at treating chronic pain and without any known side effects, unlike current drugs on the market. Sea4Pain is a first-in-class drug and has the potential to ease the suffering of billions of people globally.
Project Overview: Sea4Market
This EIC Accelerator project, called Sea4Market, will enable us to clinically validate our novel analgesic through the completion of First-in-Human trials and out-license our technology to make a rapid entry into the multi-billion Euro Chronic Pain market.
Importance of EIC Support
EIC support is essential to deliver this high-risk, high-reward project and will enable the sustainable growth of our business. We will reinvest revenues from our licensing deal back into our project pipeline to solve other unmet medical needs and ensure the sustainable growth of our company.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.035 |
| Totale projectbegroting | € 3.570.051 |
Tijdlijn
| Startdatum | 1-3-2024 |
| Einddatum | 28-2-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- SEA4US - BIOTECNOLOGIA E RECURSOS MARINHOS, S.A.penvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
A new life for people with severe disabling cluster headache: Neuromodulation therapy using safe, minimally-invasive simultaneous stimulation at the front and back of the head.Salvia BioElectronics is developing PRIMUS, a dual-site peripheral nerve modulator for drug-refractory chronic headaches, aiming for market launch by 2026 after successful clinical trials. | EIC Accelerator | € 2.499.999 | 2024 | Details |
The first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor toleranceTafalgie Therapeutics aims to develop non-opioid analgesics using innovative polypeptides from TAFA4 to provide effective, non-addictive pain relief and prevent chronic pain. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials. | EIC Accelerator | € 2.476.106 | 2022 | Details |
HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing LossHB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models. | EIC Accelerator | € 2.325.312 | 2022 | Details |
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.
A new life for people with severe disabling cluster headache: Neuromodulation therapy using safe, minimally-invasive simultaneous stimulation at the front and back of the head.
Salvia BioElectronics is developing PRIMUS, a dual-site peripheral nerve modulator for drug-refractory chronic headaches, aiming for market launch by 2026 after successful clinical trials.
The first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance
Tafalgie Therapeutics aims to develop non-opioid analgesics using innovative polypeptides from TAFA4 to provide effective, non-addictive pain relief and prevent chronic pain.
Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)
Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials.
HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss
HB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
Oral oxytocin for abdominal painThis project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens. | ERC Proof of... | € 150.000 | 2023 | Details |
Development of a Complete Triple Action Injectable Treatment for OsteoarthritisRelevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients. | EIC Transition | € 2.398.115 | 2022 | Details |
SEAFORSEAFOR verbetert de voedselveiligheid en vermindert verspilling van zeevruchten door real-time sensoren en AI-analyses te integreren. | Mkb-innovati... | € 19.980 | 2022 | Details |
SuSeaVisSuSea ontwikkelt een innovatieve conserveringstechnologie voor zeevruchten om voedselveiligheid te verbeteren en afval te verminderen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Oral oxytocin for abdominal pain
This project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens.
Development of a Complete Triple Action Injectable Treatment for Osteoarthritis
Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.
SEAFOR
SEAFOR verbetert de voedselveiligheid en vermindert verspilling van zeevruchten door real-time sensoren en AI-analyses te integreren.
SuSeaVis
SuSea ontwikkelt een innovatieve conserveringstechnologie voor zeevruchten om voedselveiligheid te verbeteren en afval te verminderen.